On December 27, it was revealed in an SEC filing that George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:LMAT) executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission uncovered LeMaitre, Chairman and CEO at LeMaitre Vascular, exercising stock options for 16,446 shares of LMAT. The total transaction was valued at $350,753.
The Thursday morning update indicates LeMaitre Vascular shares down by 0.0%, currently priced at $57.67. At this value, LeMaitre's 16,446 shares are worth $350,753.
Unveiling the Story Behind LeMaitre Vascular
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
A Deep Dive into LeMaitre Vascular's Financials
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As ...